Compare Adaptive Biotechnologies Corp (ADPT) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Brookfield Infrastructure Partners LP — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Brookfield Infrastructure Partners LP trades at $37.4 (market cap $16.97B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 5.1× Adaptive Biotechnologies Corp's market cap, and Brookfield Infrastructure Partners LP pays a 4.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BIP | |
|---|---|---|
Market Cap | $3.33B | $16.97B |
Sector | Health | Industrials |
52-Week High | $22.37 | $40.08 |
52-Week Low | $10.24 | $29.81 |
Enterprise Value | $3.19B | $78.64B |
Dividend Yield | — | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Brookfield Infrastructure Partners (BIP) trades at $37.31, up 0.81% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock carries a high P/E of 56.53 but attractive P/S of 0.71 and EV/EBITDA of 7.53. Recent earnings show volatility with two misses in the last three quarters, though Q2 2026 results are pending. The company maintains strong cash flow from operations of $6.0 billion and recently declared a $0.46 dividend.
BIP offers value through its discounted valuation and 5% yield, supported by inflation-linked contracts and infrastructure assets. However, risks include recent earnings misses, high debt levels, and sensitivity to interest rates. Analyst consensus is strongly bullish with a $45.50 price target, suggesting 22% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
